Ternary Therapeutics
85% of disease-causing proteins have no drug-binding site. Molecular glues can reach them — but until now, finding one has been mostly luck. Ternary Therapeutics just raised €4.1M to turn molecular glue discovery into an engineering discipline, starting with inflammatory and neurological disease.
Europe-Based
Preclinical
AI/ML
Small Molecule
Immunology
Why Highlight Ternary Therapeutics Now?
Ternary just closed a €4.1M seed round led by daphni — and simultaneously appointed Dr. Ian Taylor to its board. Taylor spent nine years as President of R&D at Arvinas, where he oversaw six IND filings including vepdegestrant, the PROTAC now under FDA review that could become the first approved degrader therapy. When the architect of the most advanced clinical degrader program in history joins a seed-stage molecular glue company, that’s a signal worth paying attention to.
🔭 Company Snapshot
📋 Company Overview
Ternary Therapeutics is building a computational design engine for molecular glues — small molecules that force two proteins together to trigger degradation, activation, or modulation of disease targets that conventional drugs cannot reach. About 85% of disease-causing proteins lack the binding pockets that traditional small molecules need, and while molecular glues have generated multi-billion-dollar companies and deals in targeted protein degradation, nearly all existing glues were discovered by serendipity rather than rational design.
Ternary’s platform combines physics-informed AI with rapid experimental validation in a closed loop: computational models predict candidate molecules, the wet lab tests them, and results feed back to sharpen the next round. The company is deliberately focused outside oncology — targeting inflammatory and neuroinflammatory diseases where undruggable targets are abundant and side-effect tolerance is lower, creating a higher bar for selectivity that plays to AI-driven design. Founded in late 2024, Ternary operates labs at Stevenage Bioscience Catalyst with its HQ in London and has already generated a preclinical pipeline and secured early pharma research collaborations.
🧬 Pipeline Overview
Molecular Glue Degraders — Inflammatory Disease Programs
AI-designed molecular glue degraders targeting undruggable proteins in inflammatory disease. Platform-generated candidates validated through closed-loop computational prediction and wet lab testing at Stevenage labs. Advancing toward preclinical candidate selection.
Molecular Glue Programs — Neuroinflammation
Earlier-stage programs leveraging the platform against neuroinflammatory targets — an area where molecular glues’ ability to cross the blood-brain barrier offers a structural advantage over larger degrader modalities like PROTACs.
Molecular Glue Activators — Undisclosed Targets
Beyond degradation, the platform also designs molecular glue activators — molecules that stabilize beneficial protein-protein interactions rather than triggering destruction. This broadens the platform’s therapeutic reach beyond the degrader paradigm.
⚔️ Competitive Landscape
| Company | Approach | Stage | Differentiator |
|---|---|---|---|
| Ternary Therapeutics | AI-designed molecular glues (degraders + activators) | Preclinical | Immunology-first focus; 4-module physics+AI platform; Arvinas R&D chief on board |
| Monte Rosa Therapeutics | QuEEN platform molecular glue degraders | Phase 1 | MRT-8102 85% CRP reduction; $345M raise; Novartis + Roche deals |
| TRIANA Biomedicines | Rational molecular glue degrader design | Preclinical | $120M Series B; Pfizer Ventures; oncology-first (ALK+ NSCLC) |
| Kymera Therapeutics | Pegasus platform; small molecule degraders | Phase 2 | IRAK4/STAT6 degraders; Sanofi $2B deal; $900M+ cash; public (KYMR) |
| Biotheryx | PRODEGY platform; molecular glue + bifunctional degraders | Phase 1 | BTX-1188 dual GSPT1/IKZF degrader in clinic; Cereblon expertise from founding team |
| Amphista Therapeutics | Targeted glue degraders (novel E3 approach) | Preclinical (Phase 1 planned 2026) | BMS + Merck KGaA partnerships; AMX-883 BRD9 degrader in AML |
Key insight: The molecular glue space is attracting multi-billion-dollar pharma deals — but nearly every funded company is focused on oncology. Ternary is one of very few platforms building molecular glues for immunology and neuroinflammation from day one, occupying a therapeutic niche where the bar for selectivity is higher and the competition is thinner. The Ian Taylor board appointment brings direct clinical degrader development experience that most seed-stage platforms lack entirely.
📊 Market Context
The targeted protein degradation market was valued at approximately $544M in 2024 and is projected to exceed $1.7B by 2030 at a ~21% CAGR — but the deal values tell a bigger story. In the past 18 months alone, AbbVie paid $1.64B for Neomorph’s molecular glue program, Eli Lilly committed $1.25B to Magnet Biomedicine’s TrueGlue platform, and Novartis acquired Monte Rosa’s VAV1 degrader for $2.1B+ in milestones. Platforms that can rationally design molecular glues rather than stumble onto them are exactly what pharma is paying premium prices for — and most of that deal activity has been concentrated in oncology, leaving immunology and neuro largely untapped.
🎯 Potential Impact
The unlock: If AI can turn molecular glue discovery from serendipity into engineering, the entire undruggable proteome opens up — not just in cancer, but across autoimmune, inflammatory, and neurodegenerative disease where the unmet need is enormous and the targets are abundant. The ability to design both degraders and activators from the same platform doubles the biological design space. This is the shift from finding glues to building them.
For investors: The seed is modest at €4.1M, but the board composition is disproportionately strong for this stage — Ian Taylor’s Arvinas pedigree signals that serious TPD insiders see something real in this platform. The binary question is whether Ternary can generate partnerable in vivo data in the next 12–18 months. If yes, the company enters a Series A market where molecular glue platforms are routinely commanding $50–120M rounds. The risk is execution: the platform must deliver validated hits against non-trivial immunology targets, not just computational predictions.
For pharma BD: Any large pharma building a targeted protein degradation franchise outside oncology should be watching this platform. Immunology-focused molecular glue design capability is scarce, the team comes from BenevolentAI and GSK’s Craig Crews collaboration, and the seed stage means early partnership terms are accessible. The window to engage before data inflects the valuation is now.
Ternary Therapeutics
| Founded | 2024 |
| Location | London, UK |
| Stage | Preclinical |
| Status | Private |
| Funding | €4.1M Seed |
| Lead Investor | daphni |
| Team | ~8 |
Leadership
Key Technology
Leopard — AI-powered target glueability assessment that identifies hot spots for ternary complex formation on protein surfaces, reducing failure rates in early hit discovery.
Puffin — Geometric deep learning engine that matches protein surface geometries to identify novel molecular glue binding opportunities across undruggable targets.
Octopus — Ensemble of glue-specific AI models predicting multiple facets of ternary complex binding, validated on molecular glue activity data for improved hit rates.
Gecko — Molecular dynamics simulation engine evaluating complex stability and dynamics to predict viable molecular glue interactions before synthesis.
Profile by The Biotech Voyager · FLYTE Intelligence · Data as of April 2026
